<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231136</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_115</org_study_id>
    <nct_id>NCT04231136</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Crossover Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the pharmacodynamics after single oral dosing of tegoprazan,&#xD;
      EAPA115 and RAPA115 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation Criteria&#xD;
&#xD;
        -  Pharmacodynamic assessments with intragastric pH&#xD;
&#xD;
        -  Safety assessments with adverse event monitoring including subjective/objective&#xD;
           symptoms, physical examination, vital signs, electrocardiogram, and laboratory test&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Actual">August 3, 2020</completion_date>
  <primary_completion_date type="Actual">July 29, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>The ratio of duration(Duration %) with pH ≥ 4 over 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>The ratio of duration(Duration %) with pH ≥ 6 over 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>Median pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>Mean pH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 24 hours after Investigational product administration in each period</time_frame>
    <description>Baseline pH and changes in pH after the administration of investigational products (change of duration %, change of mean pH, change of median pH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 12 hours after Investigational product administration in each period</time_frame>
    <description>The ratio of duration(Duration %) with pH ≥ 4 during nocturnal period* (*12 hours after administration of investigational product)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic Evaluation</measure>
    <time_frame>Pre-dose(0 hour) up to 12 hours after Investigational product administration in each period</time_frame>
    <description>The ratio of duration(Duration %) with pH ≥ 6 during nocturnal period* (*12 hours after administration of investigational product)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tegoprazan 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of Tegoprazan 50 mg tablet once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EAPA115</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of EAPA115 once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAPA115</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of RAPA115 once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 50 mg</intervention_name>
    <description>Tegoprazan 50 mg tablet</description>
    <arm_group_label>Tegoprazan 50 mg</arm_group_label>
    <other_name>K-CAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EAPA115</intervention_name>
    <description>EAPA115</description>
    <arm_group_label>EAPA115</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAPA115</intervention_name>
    <description>RAPA115</description>
    <arm_group_label>RAPA115</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 19 to 65 years (not inclusive) at the time of signing the informed&#xD;
             consent form (ICF).&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 17.5 and &lt; 30.5 kg/m^2 with a body weight ≥ 45 kg at&#xD;
             screening. Body mass index (kg/m^2) = weight (kg)/height (m)^2&#xD;
&#xD;
          -  Confirmed as H. pylori negative&#xD;
&#xD;
          -  A subject without any congenital or chronic disease within 3 years, and has no medical&#xD;
             examination result as pathological symptoms or signs.&#xD;
&#xD;
          -  A subject determined eligible for this study based on the screening test such as&#xD;
             clinical laboratory tests (hematology test, chemistry test, urine test, virus/bacteria&#xD;
             test, etc.), vital signs, and electrocardiogram.&#xD;
&#xD;
          -  A subject who is fully informed of the purpose and content of the study and agrees to&#xD;
             participate in the study on its own will and signs the consent form approved by the&#xD;
             Institutional Review Board (IRB) of the Seoul National University Hospital, prior to&#xD;
             participate in the study.&#xD;
&#xD;
          -  A subject who has the ability and willingness to participate throughout the whole&#xD;
             study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject with clinically significant blood, renal, endocrine, respiratory,&#xD;
             gastrointestinal, urinary, cardiovascular, hepatic, psychical, neurologic, or&#xD;
             immunologic diseases (except for simple dental past history such as tartar, impacted&#xD;
             tooth, or wisdom tooth) or evidence.&#xD;
&#xD;
          -  A subject with a history of gastrointestinal disorders (esophageal diseases such as&#xD;
             esophageal achalasia or esophageal stricture, Crohn's disease) or surgery (except for&#xD;
             simple appendectomy, herniotomy, and tooth extraction surgery) that may affect the&#xD;
             absorption of drugs.&#xD;
&#xD;
          -  A subject with the *17 allele of CYP2C19 (Ultrarapid metabolizer).&#xD;
&#xD;
          -  A subject with AST and ALT levels exceeding 3 times of the upper limit of the&#xD;
             reference range in the screening test.&#xD;
&#xD;
          -  A subject with a history of excessive caffeine (&gt; 5 units/day) or regular alcohol&#xD;
             consumption exceeding 210 g/week within 6 months of screening test. (1 glass of beer&#xD;
             (5%) (250 mL) = 10 g, 1 shot of soju (20%) (50 mL) = 8 g, 1 glass of wine (12%) (125&#xD;
             mL) = 12 g)&#xD;
&#xD;
          -  A subject who participated in other clinical trial or bioequivalence study and&#xD;
             administered the study medication within 6 months prior to the first administration of&#xD;
             the investigational product of this study.&#xD;
&#xD;
          -  A subject with significant alcohol or drug abuse within a year of screening test.&#xD;
&#xD;
          -  A subject who administered drugs that significantly induce or inhibit drug&#xD;
             metabolizing enzymes within 30 days prior to the first administration of the&#xD;
             investigational product of this study.&#xD;
&#xD;
          -  A subject who smoked cigarettes more than 20 per day within 6 months of screening&#xD;
             test.&#xD;
&#xD;
          -  A subject who administered prescribed drug or over-the-counter drug within 10 days&#xD;
             prior to the first administration of the investigational product of this study.&#xD;
&#xD;
          -  A subject who has donated whole blood within 2 months or those who donated the&#xD;
             component blood within 1 month prior to the first administration of the&#xD;
             investigational product of this study.&#xD;
&#xD;
          -  A subject who has hypersensitivity to the investigational product of this study,&#xD;
             benzimidazoles, penicillin and macrolide and its related medical history.&#xD;
&#xD;
          -  A subject with rare genetic problems such as fructose intolerance, glucose-galactose&#xD;
             malabsorption, or sucrase-isomaltase deficiency.&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  A subject who cannot use reliable contraception during the entire period of the&#xD;
             clinical trial (e.g, condom use, intrauterine device, tubal ligation, cervical cap,&#xD;
             contraceptive diaphragm, etc.).&#xD;
&#xD;
          -  A subject who is judged by the investigator to be ineligible to participate in the&#xD;
             test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In-Jin Jang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital, Dept. of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital, Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>November 29, 2020</last_update_submitted>
  <last_update_submitted_qc>November 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

